SCHEMBL7047574

SCHEMBL7047574

COc1nn(-c2ccc(NC(=O)c3ccc(Cl)cc3)c(OCc3ccc(F)cc3)c2)c(=O)o1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 3/20 0.49
MGLL Q99685 2/20 0.49
ABHD16A O95870 1/20 0.48
LPL P06858 1/20 0.47
LIPC P11150 1/20 0.47
LIPE Q05469 1/20 0.47
KDM4E B2RXH2 3/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CASP3 P42574 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
CSNK2A2 P19784 1/20 0.42
CSNK2A1 P68400 1/20 0.42
BRD4 O60885 1/20 0.41
KDM5A P29375 2/20 0.41
KDM5B Q9UGL1 2/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC8 Q9BY41 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7653362 0.90 FAAH (0.49) FAAHMGLLABHD16AKDM4ENPC1
SCHEMBL7040752 0.84 MGLL (0.57) FAAHMGLLLPLLIPCLIPE
SCHEMBL7046290 0.83 ABHD16A (0.59) FAAHMGLLABHD16ALPLLIPC
SCHEMBL7045850 0.83 MGLL (0.72) FAAHMGLLABHD16ALIPCLIPE
SCHEMBL7653357 0.80 ABHD16A (0.48) FAAHMGLLABHD16ALIPCLIPE
SCHEMBL7046310 0.78 ABHD16A (0.61) FAAHMGLLABHD16ALIPCLIPE
SCHEMBL7043172 0.75 ABHD16A (0.57) FAAHMGLLABHD16ALIPCLIPE
SCHEMBL7042468 0.73 LPL (0.60) FAAHMGLLABHD16ALPLLIPC
SCHEMBL7046269 0.73 LPL (0.71) FAAHMGLLABHD16ALPLLIPC
SCHEMBL5426287 0.73 PYGL (0.62) FAAHMGLLABHD16A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase AVENTIS PHARMA DEUTSCHLAND GMBH 2003-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase PNLIP, CEL, LIPE FAAH 142/4885MGLL 10/4885ABHD16A 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.